Cargando…
Efficacy and safety of Echinaforce® in respiratory tract infections
Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinafor...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088131/ https://www.ncbi.nlm.nih.gov/pubmed/23263637 http://dx.doi.org/10.1007/s10354-012-0166-0 |
_version_ | 1783509478683967488 |
---|---|
author | Schapowal, Andreas |
author_facet | Schapowal, Andreas |
author_sort | Schapowal, Andreas |
collection | PubMed |
description | Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment. |
format | Online Article Text |
id | pubmed-7088131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-70881312020-03-23 Efficacy and safety of Echinaforce® in respiratory tract infections Schapowal, Andreas Wien Med Wochenschr Main Topic Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment. Springer Vienna 2012-12-20 2013 /pmc/articles/PMC7088131/ /pubmed/23263637 http://dx.doi.org/10.1007/s10354-012-0166-0 Text en © Springer-Verlag Wien 2012 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Main Topic Schapowal, Andreas Efficacy and safety of Echinaforce® in respiratory tract infections |
title | Efficacy and safety of Echinaforce® in respiratory tract infections |
title_full | Efficacy and safety of Echinaforce® in respiratory tract infections |
title_fullStr | Efficacy and safety of Echinaforce® in respiratory tract infections |
title_full_unstemmed | Efficacy and safety of Echinaforce® in respiratory tract infections |
title_short | Efficacy and safety of Echinaforce® in respiratory tract infections |
title_sort | efficacy and safety of echinaforce® in respiratory tract infections |
topic | Main Topic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088131/ https://www.ncbi.nlm.nih.gov/pubmed/23263637 http://dx.doi.org/10.1007/s10354-012-0166-0 |
work_keys_str_mv | AT schapowalandreas efficacyandsafetyofechinaforceinrespiratorytractinfections |